Northwest Biotherapeutics
NWBO
NWBO was delisted on the 16th of December, 2016.
80 hedge funds and large institutions have $124M invested in Northwest Biotherapeutics in 2015 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 25 increasing their positions, 21 reducing their positions, and 8 closing their positions.
282% more capital inflows, than outflows
Capital inflows: $32.1M | Capital outflows: $8.41M
19% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 21
1.54% more ownership
Funds ownership: 36.51% → 38.05% (+1.5%)
1% more funds holding
Funds holding: 79 → 80 (+1)
3% more call options, than puts
Call options by funds: $2.74M | Put options by funds: $2.65M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Woodford Investment Management
London,
United Kingdom
|
+$26.2M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.66M |
| 3 |
Oxford Asset Management
Oxford,
United Kingdom
|
+$977K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$727K |
| 5 |
Morgan Stanley
New York
|
+$604K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Credit Suisse
Zurich,
Switzerland
|
-$3.81M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.57M |
| 3 |
Family Management
New York
|
-$482K |
| 4 |
PEAK6 Group
Chicago,
Illinois
|
-$315K |
| 5 |
D.E. Shaw & Co
New York
|
-$300K |
NWBO Hedge Fund Activity: Q4 2015 in Review
80 of the 3,823 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics (NWBO) for Q4 2015, worth a combined $124M — down 41% from $211M a quarter earlier.
Fund positioning in NWBO was balanced in Q4 2015: 8 funds opened new positions, 8 closed out, 25 added to existing stakes and 21 trimmed.
The largest buyer was Woodford Investment Management, adding an estimated $26.2M. The largest seller was Credit Suisse, cutting an estimated $3.81M.
- 80 institutional investors held Northwest Biotherapeutics (NWBO) as of Q4 2015, up from 79 in Q3 2015.
- Funds reported $124M of Northwest Biotherapeutics stock for Q4 2015, down 41% quarter-over-quarter.
- 8 funds opened new Northwest Biotherapeutics positions in Q4 2015 and 8 closed out, a net change of 0 holders.
- The largest Northwest Biotherapeutics buyer in Q4 2015 was Woodford Investment Management, an estimated $26.2M added.
- The largest Northwest Biotherapeutics seller in Q4 2015 was Credit Suisse, an estimated $3.81M sold.
Based on aggregated 13F filings for Q4 2015.